<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080560</url>
  </required_header>
  <id_info>
    <org_study_id>US/AHD/07/013</org_study_id>
    <nct_id>NCT01080560</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Cyclosporine 100mg Capsule Under Fasting Condition</brief_title>
  <official_title>A Randomized Single Dose Open Label Bioequivalence Study of Cyclosporine Capsules USP (Modified)100mg in Normal Healthy Male Subjects Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panacea Biotec Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Panacea Biotec Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate bioequivalence between Test Product (A):Cyclosporine Soft Gelatin Capsules&#xD;
      Modified 100 mg manufactured by Panacea Biotec Ltd, India and the corresponding Reference&#xD;
      Product (B):Neoral (Cyclosporine capsules,USP)Modified 100mg manufactured by Novartis&#xD;
      Pharmaceuticals Corporation, New Jersey, in 36 healthy adult male subjects under fasting&#xD;
      condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total 36 normal healthy adult male subjects will be enrolled in the study. Subjects will be&#xD;
      administered either the Test or the Reference Product with 240 mL of water in each period as&#xD;
      per the randomization schedule. Subjects will fast for at least 10 hours prior to dose&#xD;
      administration and for at least 4 hours post dose. Standardized meals will be provided in&#xD;
      each study period. Water will not be accessible to the subjects 1 hour Predose and 2 hours&#xD;
      Post dose in each period. A total of 24 blood samples will be withdrawn for pharmacokinetic&#xD;
      profiling. The whole blood concentrations of Cyclosporine will be measured by a validated&#xD;
      LC/MS/MS analytical method. Ratio analysis will be performed for untransformed and log&#xD;
      transformed pharmacokinetic parameters Cmax, AUC0-72, AUC0 inf. ANOVA will be performed on&#xD;
      log transformed pharmacokinetic parameters Cmax, AUC0-72, AUC0-inf and 90% confidence&#xD;
      interval will be constructed for the ratio of geometric least square mean of the Test and&#xD;
      Reference products, obtained from the log-transformed data. Bioequivalence will be concluded&#xD;
      if the ratio estimate as well as its 90% confidence interval, both falls within the&#xD;
      acceptable range of 80.00% to 125.00% for Cmax, AUC0-72 and AUC0-inf.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate bioequivalence between Test Product,Cyclosporine Soft Gelatin Capsules Modified 100mg of Panacea Biotec and the corresponding Reference Product, Neoral(Cyclosporine Capsule,USP)of Novartis Pharmaceutical Corporation, New Jersey</measure>
    <time_frame>upto 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To monitor the safety and tolerability in subjects receiving single dose of Cyclosporine Capsule.</measure>
    <time_frame>upto 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>NEORAL® Capsule 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine 100 mg Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Capsules USP (Modified) 100 mg</intervention_name>
    <description>Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule</description>
    <arm_group_label>Cyclosporine 100 mg Capsule</arm_group_label>
    <arm_group_label>NEORAL® Capsule 100 mg</arm_group_label>
    <other_name>Cyclosporine Capsule</other_name>
    <other_name>Gengraf Capsule</other_name>
    <other_name>Sandimmune Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects in the range of 18 - 45 years of age.&#xD;
&#xD;
          2. The healthy human subjects, whose body weight within ± 15% of ideal weight as related&#xD;
             to height and body frame according to Life Insurance Corporation (LIC) Chart (Appendix&#xD;
             A).&#xD;
&#xD;
          3. Subjects with normal findings as determined by baseline history, physical examination&#xD;
             and vital signs (blood pressure, pulse rate and body temperature).&#xD;
&#xD;
          4. Subjects with normal findings as determined by hematological tests, Serum Chemistry,&#xD;
             serological tests, urine analysis, ECG and X-ray (X-ray if taken).&#xD;
&#xD;
          5. Willingness to follow the protocol requirement as evidenced by written, informed&#xD;
             consent.&#xD;
&#xD;
          6. Agreeing to, not using any medication (either prescribed, OTC or alternate medicines),&#xD;
             including vitamins and minerals for 14 days prior to study and during the course of&#xD;
             the study.&#xD;
&#xD;
          7. No history or presence of significant alcoholism or drug abuse in the past one year.&#xD;
&#xD;
          8. Non-smokers, ex smokers and light smokers will be included. &quot;Light smokers are defined&#xD;
             as someone smoking 10 cigarettes or less per day, ex smokers as someone who completely&#xD;
             stopped smoking for at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Requiring medication for any ailment including enzyme-modifying drugs in the previous&#xD;
             28 days, before day one (1).&#xD;
&#xD;
          2. Any medical or surgical conditions, which might significantly interfere with the&#xD;
             functioning of gastrointestinal tract, blood-forming organs etc.&#xD;
&#xD;
          3. History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological,&#xD;
             metabolic or psychiatric diseases.&#xD;
&#xD;
          4. Subjects with history of recent myocardial infarction, cardiac arrhythmias, cardiac&#xD;
             failure and convulsions.&#xD;
&#xD;
          5. Participation in a clinical drug study or bioequivalence study 90 days prior to&#xD;
             present study.&#xD;
&#xD;
          6. History of malignancy or other serious diseases.&#xD;
&#xD;
          7. Refusal to abstain from food for at least ten (10.00) hours prior to drug&#xD;
             administration and for at least four (04.00) hours post dose.&#xD;
&#xD;
          8. Refusal to abstain from water for at least one (01.00) hour prior to study drug&#xD;
             administration on first day of each study period and for at least two (02.00) hours&#xD;
             post dose.&#xD;
&#xD;
          9. Any contraindication with blood sampling.&#xD;
&#xD;
         10. Refusal to abstain from smoking or consumption of tobacco products 48.00 hours before&#xD;
             dosing until last sample collection of each period.&#xD;
&#xD;
         11. Found positive in Breath alcohol test done at the time of check in for each study&#xD;
             period.&#xD;
&#xD;
         12. History of drug abuse in the past one year.&#xD;
&#xD;
         13. Use of xanthine-containing beverages or food, and grape fruit juice for 48.00 hours&#xD;
             prior to each drug dose.&#xD;
&#xD;
         14. Blood donation 90 days prior to the commencement of the study.&#xD;
&#xD;
         15. Subjects with positive HBsAg or Hepatitis-C tests or HIV tests or Anti Treponema&#xD;
             Palladium/Syphilis test.&#xD;
&#xD;
         16. Known history of hypersensitivity to Cyclosporine or to any component of the&#xD;
             formulation.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Nirav Gandhi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accutest Research Laboratories (I) Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accutest Research Laboratories (I) Pvt Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>March 3, 2010</last_update_submitted>
  <last_update_submitted_qc>March 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Arani Chatterjee</name_title>
    <organization>Panacea Biotec Ltd</organization>
  </responsible_party>
  <keyword>Bioequivalence study in healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

